Livanova Aktie

73,00 EUR +1,50 EUR +2,10 %

22:44:14

BMN

83,39 USD +2,38 USD +2,93 %

21:59:59

BTT

Livanova jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.3,86 Mrd. EUR

Div. Rendite0,00%

WKNA14156

ISINGB00BYMT0J19

SymbolLIVN

Livanova Aktien News

Sortieren:Datum Meistgelesen

06.01.25BusinesswireLivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

18.12.24BusinesswireRECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

05.12.24BusinesswireLivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

WerbungLivanova-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

14.11.24BusinesswireLivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

11.11.24BusinesswireLivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

08.10.24BusinesswireLivaNova Appoints Susan Podlogar as a New Director

25.09.24BusinesswireLivaNova to Announce Third-Quarter 2024 Results

19.08.24BusinesswireLivaNova to Present at the Baird Global Healthcare Conference

25.07.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN

19.07.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN

11.07.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN

24.06.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN

18.06.24BusinesswireLivaNova to Announce Second-Quarter 2024 Results

06.06.24BusinesswireLivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

23.05.24BusinesswireLivaNova to Present at the Goldman Sachs Healthcare Conference

30.04.24BusinesswireLivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

25.04.24BusinesswireLivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident

21.03.24BusinesswireLivaNova to Announce First-Quarter 2024 Results

20.03.24BusinesswireLivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

06.03.24BusinesswireLivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029

04.03.24BusinesswireLivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes

04.03.24BusinesswireLivaNova to Present at the Barclays Global Healthcare Conference

05.02.24BusinesswireLivaNova Announces Vladimir A. Makatsaria as CEO and Board Director

08.01.24BusinesswireLivaNova to Wind Down Advanced Circulatory Support Business Unit

04.01.24BusinesswireLivaNova to Announce Fourth-Quarter and Full-Year 2023 Results

09.11.23BusinesswireLivaNova to Present at the Piper Sandler Healthcare Conference

25.10.23BusinesswireLivaNova to Present at the Stifel and Wolfe Healthcare Conferences

21.09.23BusinesswireLivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023

20.09.23BusinesswireLivaNova to Announce Third-Quarter 2023 Results

31.08.23BusinesswireLivaNova präsentiert Essenz In-Line Blood Monitor mit U.S. FDA 510(k)-Zulassung und CE-Prüfzeichen

30.08.23BusinesswireLivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

24.08.23BusinesswireLivaNova to Present at the Baird Global Healthcare Conference

Livanova News

Livanova News: auf dieser Seite finden Sie alle Livanova News und Nachrichten zur Livanova Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Livanova News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Livanova News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.